Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 1. The Expression of SELENBP1 in Normal and Tumor Breast Tissues. Breast cancer tissue arrays were stained by immunohistochemistry using anti-human SELENBP1 antibody at 1:100 dilution. Positive stained cells are shown in dark brown color. (A) Strong positive staining of SELENBP1 in normal breast tissue under low power view (200X). (B–C) Weak positive to negative staining of SELENBP1 in breast cancer tissues under high power view (400X). (D) The Allred scoring distributions of SELENBP1 expression in normal and tumor tissue groups. Inside lines represent means and standard deviations. *p,0.05. (E) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. doi:10.1371/journal.pone.0063702.g001

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing, Staining, Immunohistochemistry, Negative Staining

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 2. SELENBP1 Expression is Progressively Reduced in Advancing Clinical Stages in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues at stage II and stage III. Inside lines represent means and standard deviations. **p,0.01. (B) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. (C) Survival curves of breast cancer patients with respect to different SELENBP1 expression levels are shown at stage II and (D) stage III. Blue and red lines represent the SELENBP1-high and SELENBP1-low groups, respectively. doi:10.1371/journal.pone.0063702.g002

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 3. The Correlation of SELENBP1 Expression with ER, PR, and TP53 in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues with ER+ and ER– status. The inside lines represent means and standard deviations. **p,0.01. The difference between normal and ER+ and ER– tumor tissues was analyzed by Kruskal-Wallis test and statistical results are shown (B). Survival curves of breast cancer patients with respect to different SELENBP1 expression are shown in ER+ group in (C). The blue line is the SELENBP1- high group and the red line is the SELENBP1-low group. The scoring distributions of SELENBP1 expression in normal and tumor tissues with PR+/PR–

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: TGF-β and TNF-α interaction promotes the expression of MMP-9 through H3K36 dimethylation: implications in breast cancer metastasis

doi: 10.3389/fimmu.2024.1430187

Figure Lengend Snippet: MMP-9 expression is associated with TGF-β and TNF-α in breast cancer tissues. Immunohistochemical staining was done for MMP-9, TGF-β, and TNF-α expressions. Tissue microarray TMA slides (88 breast cancer tissues from breast cancer patients) were subjected to immunohistochemistry using antibodies against MMP-9, TGF-β, and TNF-α. Based on IHC staining intensities of TGF-β and TNF-α, patients’ samples were divided into four groups (Low TNF-α- Low TGF-β; Low TNF-α- High TGF-β; High TNF-α- Low TGF-β; High TNF-α- High TGF-β. (A) Scatter Plot Graph for TNF-α and TGF-β. (B) Scatter Plot Graph for TNF-α and TGF-β with indication of patients with primary cancer, metastasis and normal breast cancer tissues. (C) MMP-9 expression was elevated in the breast cancer tissues (n=24 patients) having high levels of TGF-β and TNF-α compared to the tissues (n=20 patients) having less TGF-β and TNF-α. (D) Representative IHC images of the samples of breast cancer tissues with low levels of MMP-9, TGF-β and TNF-α. (E) Representative IHC images of the samples of breast cancer tissues showing high levels of MMP-9, TGF-β and TNF-α. All data is presented as the mean ± SD. *p < 0.05.

Article Snippet: Ethical approval was not required for the studies involving humans because We purchased commercial breast cancer tissue microarray (TMA) from US Biomax Inc.(BRM961a) https://www.tissuearray.com/tissue-arrays/Breast/BRM961b ; TissueArray.Com LLC 1(5885 Crabbs Branch Way, Derwood, MD 20855, USA.

Techniques: Expressing, Immunohistochemical staining, Staining, Microarray, Immunohistochemistry